Development of cholesterol-based conjugates for targeted drug delivery

S.T.P. Pharma Sciences

Volumn 13, Issue 1, 2003, Pages 27-35

  Alanazi, F ^a   Halpern, D S ^b   Lu, D R ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Isotron Inc   (United States)

Author keywords

Cholesterol; Diagnosis; Drug design; Drug targeting; Tumor; Virus

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CHOLESTEROL; CORDYCEPIN; IODOCHOLESTEROL I 131; IOPANOIC ACID; IOPANOIC ACID CHOLESTEROL ESTER; SELENIUM DERIVATIVE; SELENOMETHYLNORCHOLESTEROL SE 37; UNCLASSIFIED DRUG;

ADRENAL DISEASE; ANTIVIRAL ACTIVITY; ATHEROSCLEROSIS; CONJUGATE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; ISOTOPE LABELING; LIVER DISEASE; OVARY DISEASE; REVIEW; TUMOR; VIRUS INFECTION;

EID: 0037227252     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. REILLY W.J. - Pharmaceutical necessities. - In: Remington: the Science and Practice of Pharmacy, A.R. Gennaro Ed., Mack Printing Company, Easton, Pennsylvania, 9th, Vol. 2, 1995, p. 1397.
2. OHVO-REKILA H. et al. - Cholesterol interactions with phospholipids in membranes. - Progress in Lipid Research, 41, 66-97, 2002.
3. YEAGLE P.L. - Cholesterol and cell membrane. - In: Biology of Cholesterol, P.L. Yeagle Ed., CRC Press, Boca Raton, Florida, 1988, pp. 121-146.
4. FINEAN F.B. - Interaction between cholesterol and phospholipid in hydrated bilayers. - Chem. Phys. Lipids, 54, 147-156, 1990.
5. PROKSCH E. - The epidermis as metabolically active tissue: regulation of lipid synthesis by the barrier function. - Z. Hautkr., 65, 296-300, 1990.
6. GIBBONS G.F., MITROPOULOS K.A., MYANT N.B. - Biochemistry of Cholesterol. - Elsevier, Amsterdam, 1982, p. 369.
7. COOK R.P. - Distribution of sterols in organisms and in tissues. - In: Cholesterol, Chemistry, Biochemistry, and Pathology, R.P. Cook Ed., Academic Press, New York, 1958, pp. 146-180.
8. 131l-19-iodocholesterol. - N. Engl. J. Med., 285, 1387-1393, 1971.
9. BUI F., MACRI C., VAROTTO L., BOSCARO M., MANTERO F. - Adrenal scintigraphy in the morphological and functional evaluation of Cushing's syndrome. - Cardiology, 72, 76-83, 1985.
10. 131l-19-iodocholesterol scintigraphy of the adrenal cortex. - Acta Enocrinol., 80, 81-94, 1975.
11. 131l-19-iodocholesterol. - Br. J. Radiol., 50, 340-349, 1977.
12. GROSS M.D., SHAPIRO B., FRANCIS I.R., GLAZER G.M., BREE R.L., ARCOMANO M.A., SCHTEINGART D.E., McLEOD M.K., SANFIELD J.A., THOMPSON N.W. - Scintigraphy evaluation of clinically silent adrenal masses. - J. Nucl. Med., 35, 1145-1152, 1994.
13. KAZEROONI E.A., SISSON J.C., SHAPIRO B., GROSS M.D., DRIEDGER A., HURWITZ G.A., MATTAR A.G., PETRY N.A. - Diagnostic accuracy and pitfalls of [iodine-131] 6-beta-iodomethyl-19-norcholesterol (NP-59) imaging. - J. Nucl. Med., 31, 526-534, 1990.
14. HARRIS R.D., HERWIG K.R. - Unusual cause for recurrent Cushing syndrome and its diagnosis by compouted tomography and NP-59 radiocholesterol scanning. - Urology, 36, 277-279, 1990.
15. GUMS J.G., WILT V.M, - Disorders of the adrenal gland. - In: Pharmacotherapy, A Pathophysiologic Approach, J.T. Dipiro Ed., Appleton & Lange, Connecticut, 1997, pp, 1547-1583.
16. HAWKINS L.A., B RRITTON K.E., SHAIRO B. - Selenium-75 selenomethyl cholesterol: a new agent for quantitive functional scintigraphy of the adrenals: physical aspects. - Br. J. Radiol., 53, 883-889, 1980.
17. MILLER J.L., SMITH J. A., MERVIS, B., ROMAN, T. - Selenium-75 imaging and computed tomography of the adrenal glands in differentiating the cause of Cushing's syndrome. - S. Afr. Med. J., 63, 848-850, 1983.
18. SHAPIRO B., BRITTON K.E., HAWKINS L.A., EDWARDS C.R.W. - Clinical experience with 75 Se selenomethylcholesterol adrenal imaging. - Clin. Endocrinol., 15, 19-27, 1981.
19. CHATAL J.F., CHARBONNEL B., GUIHARD D. - Radionuclide imaging of the adrenal glands. - Clin. Nucl. Med., 3, 71-76, 1978.
20. JOHNSON S.D., WELCH M.J. - Synthesis, biological and baboon PET imaging of the potential adrenal imaging agent cholesteryl-p-[18 F] fluorobezoate. - Nucl. Med. Biol., 26, 131-138, 1999.
21. VAN DORT M., SCHWENDNER S.W., SKINNER R.W.S., GROSS M.D., COUNSELL R.E. - Potential tumor or organ-imaging agents. 24. Radioidinated pregenolone esters. - Steroid., 44, 85-93, 1984.
22. DEAN P.B., KIVISAARI L., KORMANO M. - The diagnostic potential of contrast enhancement pharmacokinetics. - Invest. Radiol., 13, 533-540, 1978.
23. GLAZER G.M., LONGINO M.A., SCHWENDNER S.W., COUNSELL R.E., WEICHERT J.P. - Lipid soluble contrast agents for computed tomography of the liver: results with cholesteryl iopanoate. - J. Comput. Assist. Tomogr., 7, 775-779, 1983.
24. LONGINO M.A., WEICHERT J.P., SCHWENDNER S.W., SZABO S.M., COUNSELL R.E., GLAZER G.M. - Biodistribution of a new lipid-soluble CT contrast agent. Evaluation of cholesteryl iopanoate in the rabbit. - Invest. Radiol., 18, 275-278, 1983.
25. LONGINO M.A., GLAZER G.M., WEICHERT J.P., GROZIAK M.P., SCHWENDNER S.W., COUNSELL R.E. - Esters of iopanoic acid as liver-specific CT contrast agents: biodistribution and CT evaluation. - J. Comput. Assist. Tomogr., 8, 1099-1104, 1984.
26. BASAVARAJU S.R., JONES T.D. - Atherosclerotic risks from chemicals. I. Toxicological observations and mechanisms of atherosclerosis. - Arch. Environ. Contam. Toxicol., 35, 152-64, 1998.
27. BAGNOLI L., BELLESI R., MENEGAZZO G., MEUCCI I., GHETTI A. - The risk factors of atherosclerotic disease. Life style and primary prevention. - Recenti Prog. Med., 85, 195-203, 1994.
28. FURLOW B. - Coronary artery disease and electron-beam CT. - Radiol. Technol., 73, 126-35, 2001.
29. BEERS M.H., BERKOW R. - Atherosclerosis. -In: The Merck Manual of Diagnosis and Therapy, Merck& Co, West Point, PA, 1999, pp. 1655-1658.
30. GERRITY R.G. - The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. - Am. J. Pathol., 103, 181-190, 1981.
31. McKENNEY J.M. - Dyslipidemias. - In: Applied Therapeutics: The Clinical Use of Drugs, L.Y. Young, M.A. Koda-Kimble Eds., Applied Therapeutics, Vancouver, WA, 1995, pp. 9-23.
32. PENTIKAINEN M.O., ALA-KORPELA O.M., KOVANEN P.T. - Modified LDL-trigger of atherosclerosis and inflammation in arterial intima. - J. Internal Med., 247, 359-370, 2000.
33. 123l-low density lipoprotein. - Eur. J. Nucl. Med., 12, 291-292, 1986.
34. SINZINGER H., ANGELBERGER P. - Imaging and kinetic studies with radiolabelled autologous low density lipoprotein (LDL) in human atherosclerosis. - Nucl. Med. Comm., 9, 859-866, 1988.
35. ATSMA D.E., FEITSMA R.I., CAMPS J., VAN'T HOOFT F.M., VAN DER WALL E.E., NIEUWENHUIZEN W., PAUWELS E.K. - Potential of 99Tc-LDLs labelled by different methods for scintigraphic detection of experimental atherosclerosis in rabbits. - Arteriosclerosis Thrombosis, 13, 78-83, 1993.
36. 111In-labelled low density lipoprotein. - Proc. Int. Atherosclerosis Congress, Vienna, 1989, p. A219.
37. ROSEN J.M., BUTLER S.P., MEINKEN G. E., WANG T.S.T., RAMAKRISHAN R., SRIVASTAVA S.C., ALDERSON P.O., GINSBERG H.N. - Indium-111 labelled LDL: a potential agent for imaging atherosclerosis disease and lipoprotein distribution. - J. Nucl. Med., 31, 343-350, 1990.
38. ROBERT A.B., LEES A.M., LEES R.S., STRAUSS H.W., FALLON J.T., TAVERAS J., KOPIWODA S. - Selective accumulation of low density lipoproteins in damaged arterial wall. - J. Lipid Res., 24, 1160-1167, 1983.
39. 131l-low-density lipoprotein imaging in patients with hypertension and early atherosclerotic lesions in the carotid artery. - Vasa, 28, 185-189, 1999.
40. RODRIGUES M., GRANEGGER S., KRITZ H, SINZINGER H. - Unusual imaging of varicose veins after radiolabeling of autologous low-density lipoproteins. - Rev. Esp. Med. Nucl., 17, 442-445, 1998.
41. XIAO W., WANG T., SCOTT T., COUNSELL R.E., LIU H. - Radiolabelled cholesteryl iopanoate/acetylated low density lipoprotein as a potential probe for visualization of early atherosclerosis lesion in rabbits. - Pharm. Res., 16, 420-426, 1999.
42. ROSOWSKY A., FU H., PAI N., MELLORS J., RICHMAN D.D., HOSTETLER K.Y. - Synthesis and in vitro activity of long-chain 5′-O-[(alkoxycarbonyl)phosphinyl]-3′-azido-3′- deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1. - J. Med. Chem., 40, 2582-2490, 1997.
43. BOUTORINE A.S., KOSTINA E.V. - Reversible covalent attachment of cholesterol to oligodeoxyribonucleotides for studies of the mechanisms of their penetration into eucaryotic cells. - Biochimie, 75, 35-41, 1993.
44. JEANINE R. - Lipids and retroviruses. - Lipids, 35, 123-130, 2000.
45. WASNER M., HENDERSON E. E., SUHADOLNIK R.J., PFLLEIDERER W. - Synthesis, characterization, and biological activity of monomeric and trimeric cordycepin-cholesterol conjugates and inhibition of HIV-1 replication. - Helv. Chim. Acta., 79, 619-633, 1996.
46. LETSINGER R.L., ZHANG G., SUN D.K., IKEUCHI T., SAPRIN S.P. - Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. - Proc. Natl. Acad. Sci. USA, 86, 6553-6776, 1989.
47. STEIN C.A, PAL R., DEVICO A.L., HOKE G., MUMBAUER S., KINSTLER O., SARNGADHARAN M.G., LETSINGER R.L - Mode of action of 5′-linked cholesteryl phosphothoate oligodeoxynucleotides in inhibiting syncytia and infection by HIV-1 and HIV-2 in vitro. - Biochemistry, 30, 2439-2444, 1991.
48. MOHAN P., LOYA S., AVIDAN O., VERMA S., DHINDSA G.S., WONG M.F., HUANG P.P., YASHRIO M., BABA M., HIZI A. - Synthesis of naphtahalenesulfonic acid small molecules as selective inhibitors of the DNA polymerase and ribonulclease H activity of HIV-1 reverse. -J. Med. Chem., 37, 2513-2519, 1994.
49. GALABOV A.S., NIKOLAEVA L., TODOROVA D., MILKOVA T. - Antiviral activity of cholesteryl esters of cinnamic acid derivatives. - Z. Naturforsch. [C], 53, 883-887, 1998.
50. SERGHERAERT C., PIERLOT C., TARTAR A., HENIN Y., LEMAITRE M. - Synthesis and anti-HIV evaluation of D4T and D4T 5′-monophosphate prodrugs. - J. Med. Chem., 36, 826-830, 1993.
51. SQALLI-HOUSSAINI H., PIERLOT C., KUSNIERZ J.P., PARMENTIER B., MARTIN-NIZARD F., LESTAVEL-DELATTRE S., TARTAR A., FRUCHART J.C., SERGHERAERT C., DURIEZ P. - Preparation of anti-HIV-low-density lipoprotein complexes for delivery of anti-HIV drugs via the low-density lipoprotein pathways. - Biotechnol Ther., 5, 69-85, 1994
52. SIPERTEIN M.D. - Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. - J. Lipid Res., 25, 1462-1468, 1984.
53. SHAWER M., GREENSPAN P., ØIE S., LU D.R. - VLDL-resembling phospholipid-submicron emulsion for cholesterol-based drug targeting. - J. Pharm. Sci., 2002 (in press).
54. LASTER B.H., KAHL S.B., POPENOE E.A., PATE D.W., FAIRCHILD R.G. - Biological efficacy of boronated low-density lipoprotein for boron neutron capture therapy as measured in cell culture. - Cancer Res., 51, 4588-4593, 1991.
55. NYDEGGER U.E., BULTER R.E. - Serum lipoprotein levels in patients with cancer. - Cancer Res., 32, 1756-1760, 1972.
56. ALEXOPOULOS C.G., BLATSIOS B., AVGERINOS A. - Serum lipids and lipoprotein disorders in cancer patients. - Cancer, 60, 3065-3070, 1987.
57. CHAO F.C., EFRON B., WOLF P. - The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy. - Cancer, 35, 1223-1229, 1975.
58. HO Y.K, SMITH R.G., BROWN M.S., GOLDSTEIN J.L. - Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukaemia cells. - Blood, 52, 1099-1104, 1978.
59. GUEDDARI N., FAVRE G., HACHEM H., MAREK E., LE GAILLARD F., SOULA G. - Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549. -Biochimie, 75, 811-819, 1993.
60. FIRSTONE R.A. - Low density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. - Bioconjugate Chem., 5, 105-113, 1994.
61. YEN C.F., KALUNTA C.I., CHEN F.S., KAPTEIN J.S., LIN C.K., LAD P.M. - Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt's lymphoma cells. - Biochim. Biophys. Acta., 1257, 47-57, 1995.
62. MALETINSKA L., BLAKELY E.A., BJORNSTAD K.A., DEEN D.F., KNOFF L.J., FORTE T.M. - Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. - Cancer Res., 60, 2300-2303, 2000.
63. CHEN W., METHA S., LU D.R. - Selective boron drug delivery to brain tumors for boron neutron capture therapy. - Adv. Drug Delivery Reviews, 26, 231-247, 1997.
64. KRIEGER M., GOLDSTEIN J.L., BROWN M.S. - Receptor-mediated uptake of low density lipoprotein reconstituted with 25-hyroxycholesterol oleate suppressor 3-hydroxy-3-methylglutaryl-coenzyme A reductase and inhibits growth of human fibroblasts. - Proc. Natl. Acad. Sci., 75, 5052-5056, 1978.
65. LUNDBERG S. - Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. - Cancer Res., 47, 4105-4108, 1987.
66. LESTAVEL-DELATTRE S., MARTIN-NIZARD F., CLAVEY V., TESTARD P., FAVRE G., DOUALIN G. - Low density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. - Cancer Res., 52, 3629-3635, 1992.
67. KERR D.J., HYNDS S.A., SHEPHERD J., PACKARD C.J., KAYE S.B. - Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumor cell monolayer. - Biochem. Pharmacol., 37, 3981-3986, 1988.
68. REDDI E. - Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumors. - J. Photochem. Photobiol. B: Biology, 37, 189-195, 1997.
69. REDDI E., ZHOU C., BIOLO R., MENEGALDO E., JORI G. - Liposome or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumors. I. Pharmacokinetic properties and phototherapeutic efficiency. - Br. J. Cancer, 61, 407-411, 1990.
70. DE SMIDT P.C., VAN BERKEL T.J. - Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein. - Cancer Res., 50, 7476-7482, 1990.
71. VITOLS S., SODERBERG-REID K., MASQUELIER M., SJOSTROM B., PETERSON C. - Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. - Br. J. Cancer, 62, 724-729, 1990.
72. FIRESTONE R.A, PISANO J.M., FLALCK J.R., McPHAUL M.M., KREIEGER M. -Selective deliver of cytotoxic compounds to cells by the LDL pathway. - J. Med. Chem., 27, 1037-1043, 1984.
73. HALBERT G.W., STUART J.F.B., FLORENCE A.T. - The incorporation of lipid soluble antinewplastic agents into microemulsions-protein-free analogues of low density lipoprotein. - Int. J. Pharm., 21, 219-232, 1984.
74. VERSLUIS A.J., PUMP E.T., RENSEN P.C.N., VAN BERKEL J.C., BIJSTERBOSCH M.K. - Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. - Pharm. Res., 15, 531-537, 1998.
75. VERSLUIS A.J., PUMP E.T., RENSEN P.C.N., VAN BERKEL J.C., BIJSTERBOSCH M.K. - Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. - J. Pharmacol. Exp. Ther., 289, 1-7, 1999.
76. HYNDS S.A. - Cancer chemotherapy: use of low density of lipoproteins as targeting vehicles and treatments. - Thesis, University of Glasgow, UK, 1986.
77. SALOMONE B., PONTI R., GASCO M.R., UGAZIO E., QUAGLINO P., OSELLA-ABATE S., BERNEGO M.G. - In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid prodrug on melanoma cells: evaluation of ant proliferative activity and apoptosis induction. - Clin. Exper. Metastasis, 18, 663-673, 2001.
78. PENG H., ZALKOW L.H., ABRAHAM R.T., POWIS G. - Novel CDC25A phosphatase inhibitors from pyrolysis of 3-alpha-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel. - J. Med. Chem., 41, 4677-4680, 1998.
79. PENG H., XIE W., OTTERNESS D.M., COGSWELL J.P., MCCONNELL R.T., CARTER H.L., POWIS G., ABRAHAM R.T., ZALKOW L.H. - Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase. - J. Med. Chem., 44, 834-8348, 2001.
80. PENG H., XIE W., KIM D., ZALKOW L.H., POWIS G., OTTERNESS D.M., ABRAHAM R.T. - Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase. - Biooorganic & Medicinal Chemistry, 8, 299-306, 2000.
81. JI B., PEACOCK G., LU D.R. - Synthesis of cholesterol-carborane conjugate for targeted drug delivery. - Bioorganic & Medicinal Chemistry Letters, 2002 (in press).
82. ALANAZI F., LI H., HALPERN D. S., ØIE S., LU D.R. - Synthesis, preformulation and liposomal formulation of cholesteryl carborane esters with various fatty chains. - Int. J. Pharm., 2002 (submitted).
83. PEACOCKG., LU D.R. - Targeted drug delivery for brain cancer using a carborane mimic of a cholesterol ester: cell cultural studies. - Ph.D. Thesis, The University of Georgia, 2001.
84. PEACOCK G., SIDWELL R., PAN G., ØIE S., LU D.R. - In vitro uptake of a new cholesteryl carborane ester compound in human glioma cell lines. - Pharm. Res., 2002 (submitted).
85. KADER A., DAVIS P.J., KARA M., LIU H. - Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. - J. Control. Rel., 55, 231-243, 1998.
86. CHEN P., BODOR N., WU W.M., PROKAI L. - Strategies to target kyotorphin analogues to the brain. - J. Med. Chem.,41, 3773-3781, 1998.
87. EL KIHEL L., BOURASS J., RICHOMME P., PETIT J.Y., LETOURNEUX Y. - Synthesis and evaluation of the anti-inflammatory effects of niflumic acid lipophilic prodrugs in brain edema. - Arzneimittelforschung, 46, 1040-1044, 1996.
88. PROKAI L., PROKAI-TATRAI K., OUYANG X., KIM H.S., WU W.M., ZHARIKOVA A., BODOR N. -Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue. - J. Med. Chem., 42, 4563-4571, 1999.
89. YOON S.H., WU J., WU W.M., PROKAI L., BODOR N. - Brain-targeted chemical delivery of [Leu2, Pip3]-TRH: synthesis and biological evaluation. - Bioorg. Med. Chem., 8, 1059-1063, 2000.
90. PROKAI-TATRAI K., PROKAI L., BODOR N. - Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. - J. Med. Chem., 39, 4775-4782, 1996.
91. MERESSE S., DELBART C., FRUCHART J.C., CECCHELLI R. - Low-density lipoprotein receptor on endothelium of brain capillaries. - J. Neurochem., 53, 340-345, 1989.
92. LUCARELLI M., GENNARELLI M., CARDELLI P., NOVELLI G., SCARPA S., DALLAPICCOLA B. STROM R. - Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. - FEBS Letters, 401, 53-58, 1997.
93. ADES A., CARVALHO J.P., GRAZIANI S.R., AMANCIO R.F., SOUEN J.S., PINOTTI J.A., MARANHAO R.C. - Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. - Gynecol. Oncol., 82, 84-87, 2001.
94. KELLNER-WEIBEL G., GENG Y.J., ROTHBLAT G.H. - Cytotoxic cholesterol is generated by the hydrolysis of cytoplasmic cholesteryl ester and transported to the plasma membrane. - Atherosclerosis, 146, 309-319, 1999.
95. DE SMIDT P.C., LE DOAN T., DE FALCO S., VAN BERKEL T.J. -Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. - Nucleic Acids Res.,19, 4695-4700, 1991.